Pure seminoma: A review and update

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Boujelbene, Noureddine ^a,b,d   Cosinschi, Adrien ^a   Boujelbene, Nadia ^c,e   Khanfir, Kaouthar ^a,d   Bhagwati, Shushila ^a   Herrmann, Eveleyn ^a   Mirimanoff, livRene Oier ^a   Ozsahin, Mahmut ^a   Zouhair, Abderrahim ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Hopital de Sion   (Switzerland)

^e HABIB THAMEUR HOSPITAL   (Tunisia)

Author keywords

Chemotherapy; Radiotherapy; Seminoma; Surveillance; Treatment

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; EARLY CANCER; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; PROGNOSIS; RARE DISEASE; REVIEW; SEMINOMA; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; BIOPSY; CLINICAL TRIAL (TOPIC); MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; RADIOTHERAPY; RECURRENT DISEASE; TESTIS TUMOR;

ADOLESCENT; ADULT; BIOPSY; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LYMPHATIC METASTASIS; MALE; MEDICAL ONCOLOGY; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY; RECURRENCE; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 79961113368     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-90     Document Type: Review

References (99)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. Levi F, Te VC, Randimbison L, La Vecchia C. Trends in testicular cancer incidence in Vaud, Switzerland. Eur J Cancer Prev 2003, 12(4):347-9. 10.1097/00008469-200308000-00017, 12883390.
3. Khan O, Protheroe A. Testis Cancer. Postgrad Med J 2007, 83(984):624-32. 10.1136/pgmj.2007.057992, 2600126, 17916870.
4. Heidenreich A, Weissbach L, Höltl W, Albers P, Kliesch S, Köhrmann KU, DIeckmann KP, . German Testicular Cancer Study Group German Testicular Cancer Study Group. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001, 166(6):2161-5. 10.1016/S0022-5347(05)65526-7, 11696727, German Testicular Cancer Study Group.
5. Mottet N, Culine S, Iborra F, Avances C, Bastide C, Lesourd A, Michel F, Rigaud J. Testicular tumors. Prog Urol 2007, 17(6):1035-45. 10.1016/S1166-7087(07)74779-6, 18153986.
6. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in non seminomatous testis cancer. J Urol 1982, 128:315-20.
7. Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V, . ESMO Guidelines Working Group Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(5):140-6. 10.1093/annonc/mdq176, 19887468, ESMO Guidelines Working Group.
8. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary?. J Urol 1995, 153(3 Pt 2):981-5.
9. Pizzocaro G, Nicolai N, Salvioni R. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. World J Urol 1994, 12(3):113-9.
10. Kiricuta IC, Sauer J, Bohndorf W. Omission of the pelvic irradiation in Stage I testicular seminoma: A study of postorchiectomy paraaortic radiotherapy. Int J Radiat Oncol Biol Phys 1996, 35(2):293-8. 10.1016/0360-3016(96)00093-4, 8635936.
11. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008, 53(3):478-96. 10.1016/j.eururo.2007.12.024, 18191324.
12. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002, 20(22):4448-52. 10.1200/JCO.2002.01.038, 12431967.
13. Bobba VS, Mittal BB, Hoover SV, Kepka A. Classical and anaplastic seminoma: difference in survival. Radiology 1988, 167(3):849-52.
14. Warde P, Gospodarowicz MK, Banerjee D, Panzarella T, Sugar L, Catton CN, Sturgeon JF, Moore M, Jewett MA. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 1997, 157(5):1705-9. 10.1016/S0022-5347(01)64839-0, 9112510.
15. Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF, Moore M, Goodman P, Jewett MA. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995, 13(9):2255-62.
16. Kamba T, Kamoto T, Okubo K, Teramukai S, Kakehi Y, Matsuda T, Ogawa O. Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol 2010, 17(12):980-7. 10.1111/j.1442-2042.2010.02645.x, 3017741, 20955354.
17. Dieckmann KP, Brüggeboes B, Pichlmeier U, Küster J, Müllerleile U, Bartels H. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient?. Urology 2000, 55(1):102-6. 10.1016/S0090-4295(99)00376-3, 10654903.
18. Oliver RT, Mead GM, Fogarty PJ, Stenning SP, . MRC TE19 and EORTC 30982 trial collaborators Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (abstract). Proc Am Soc Clin Oncol 2008, 26. 1 (Part II, 1006s), MRC TE19 and EORTC 30982 trial collaborators.
19. Warde PR, Chung P, Sturgeon J, Panzarella T, Giuliani M, Tew-George B, Jewett M, Bayley A, Moore M, Catton C, Gospodarowicz M. Should surveillance be considered the standard of care in stage I seminoma? J: Clin. Oncol (Meeting Abstracts) 2005, 23:4520.
20. Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular Seminoma. Br J Cancer 1992, 65(5):775-8. 10.1038/bjc.1992.164, 1977398, 1586607.
21. von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M, Rørth M, Schultz H. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993, 29A(14):1931-4.
22. Kollmannsberger C, Tyldesley S, Moore C, Chi KN, Murray N, Daneshmand S, Black P, Duncan G, Hayes-Lattin B, Nichols C. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2011, 22(4):808-14. 10.1093/annonc/mdq466, 20926549.
23. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF, Boice JD. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997, 89(19):1429-39. 10.1093/jnci/89.19.1429, 9326912.
24. Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD, Dores GM, Gilbert ES. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005, 97(18):1354-65. 10.1093/jnci/dji278, 16174857.
25. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008, 19(3):443-7.
26. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003, 21(8):1513-23. 10.1200/JCO.2003.04.173, 12697875.
27. Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv 2008, 2(3):128-37. 10.1007/s11764-008-0054-1, 18792787.
28. Mulla MG, Ananthkrishnan G, Mirza MS, Bungay P, Puri S, Chakraborti P. Renal artery stenosis after radiotherapy for stage I seminoma, a case report. Clin Oncol (R Coll Radiol) 2007, 19(3):209.
29. Sharda NN, Kinsella TJ, Ritter MA. Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. J Clin Oncol 1996, 14(11):2933-9.
30. Buchholz TA, Walden TL, Prestidge BR. Cost-effectiveness of posttreatment surveillance after radiation therapy for early stage seminoma. Cancer 1998, 82(6):1126-33. 10.1002/(SICI)1097-0142(19980315)82:6<1126::AID-CNCR17>3.0.CO;2-8, 9506359.
31. Fosså SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U:S: men. J Natl Cancer Inst 2005, 97(14):1056-66. 10.1093/jnci/dji185, 16030303.
32. Culine S, Michel F, Rocher L, Mottet N, Davin JL. Comité de Cancérologie de l'Association Française d'Urologie. Follow-up of testicular germ cell tumours. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie. Prog Urol 2005, 15(4):593-6.
33. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part II:. Eur Urol 2008, 53(3):497-513. 10.1016/j.eururo.2007.12.025, 18191015.
34. National Comprehensive Cancer Network clinical practice guidelines in oncology testicular cancer V:1; 2011. , http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
35. Hunter M, Peschel RE. Testicular seminoma. Results of the Yale University experience, 1964-1984. Cancer 1989, 64(8):1608-11. 10.1002/1097-0142(19891015)64:8<1608::AID-CNCR2820640809>3.0.CO;2-1, 2790671.
36. Thomas GM. Is "optimal" radiation for stage I seminoma yet defined?. J Clin Oncol 1999, 17(9):3004-5.
37. Classen J, Schmidberger H, Meisner C, Winkler C, Dunst J, Souchon R, Weissbach L, Budach V, Alberti W, Bamberg M, . German Testicular cancer study Group (GTCSG), German Testicular cancer study Group Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study. Br J Cancer 2004, 90(12):2305-11. 2409532, 15150576, German Testicular cancer study Group (GTCSG), German Testicular cancer study Group.
38. Logue JP, Harris MA, Livsey JE, Swindell R, Mobarek N, Read G. Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 2003, 57(5):1304-9. 10.1016/S0360-3016(03)00754-5, 14630266.
39. Melchior D, Hammer P, Fimmers R, Schüller H, Albers P. Long term results and morbidity of paraaortic compared with paraaortic and iliac adjuvant radiation in clinical stage I seminoma. Anticancer Res 2001, 21:2989-93.
40. Zwahlen DR, Martin JM, Millar JL, Schneider U. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2008, 70(3):853-8. 10.1016/j.ijrobp.2007.10.007, 18164856.
41. Jacobsen KD, Olsen DR, Fosså K, Fosså SD. External beam abdominal radiotherapy in patients with seminoma stage I: field type, testicular dose, and spermatogenesis. Int J Radiat Oncol Biol Phys 1997, 38(1):95-102. 10.1016/S0360-3016(96)00597-4, 9212009.
42. Power RE, Kennedy J, Crown J, Fraser I, Thornhill JA. Pelvic recurrence in stage I seminoma: a new phenomenon that questions modern protocols for radiotherapy and follow-up. Int J Urol 2005, 12(4):378-82. 10.1111/j.1442-2042.2005.01114.x, 15948726.
43. Fosså SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reed NS, Widmer B, Stenning SP. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor. J Clin Oncol 1999, 17(4):1146.
44. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European organisation for the research and treatment of cancer trial 30942 (ISRCTN18525328). J Clin Oncol 2005, 23(6):1200-8. 10.1200/JCO.2005.08.003, 15718317.
45. Milosevic MF, Gospodarowicz M, Warde P. Management of testicular seminoma. Semin Surg Oncol 1999, 17(4):240-9. 10.1002/(SICI)1098-2388(199912)17:4<240::AID-SSU4>3.0.CO;2-Q, 10588852.
46. Fosså SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989, 16(2):383-8. 10.1016/0360-3016(89)90334-9, 2921142.
47. Oldenburg J, Martin JM, Fosså SD. Late relapses of germ cell malignancies - incidence, management, and prognosis. J Clin Oncol 2006, 24(35):5503-11. 10.1200/JCO.2006.08.1836, 17158535.
48. Coleman JM, Coleman RE, Turner AR, Radstone CR, Champion AE. The management and clinical course of testicular seminoma: 15 years' experience at a single institution. Clin Oncol (R Coll Radiol) 1998, 10(4):237-41.
49. Santoni R, Barbera F, Bertoni F, De Stefani A, Livi L, Paiar F, Scoccianti S, Magrini SM. Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only. BJU Int 2003, 92(1):47-52. 10.1046/j.1464-410X.2003.04273.x, 12823382.
50. Borge N, Fosså SD, Ous S, Stenwig AE, Lien HH. Late recurrence of testicular cancer. J Clin Oncol 1988, 6(8):1248-53.
51. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 2008, 26(24):3937-42. 10.1200/JCO.2008.16.5043, 2867767, 18711182.
52. Fosså SD, Oldenburg J, Dahl AA. Short- and long-term morbidity after treatment for testicular cancer. BJU Int 2009, 104(9 Pt B):1418-22.
53. Hanks GE, Peters T, Owen J. Seminoma of the testis: Long-term beneficial and deleterious effects of radiation. Int J Radiat Oncol Biol Phys 1992, 24:913-919. 10.1016/0360-3016(92)90475-W, 1447034.
54. Richiardi L, Scélo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, Weiderpass E, Tracey E, Brewster DH, McBride ML, Kliewer EV, Tonita JM, Pompe-Kirn V, Kee-Seng C, Jonasson JG, Martos C, Brennan P. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 2007, 120(3):623-31. 10.1002/ijc.22345, 17096341.
55. Martin JM, Joon DL, Ng N, Grace M, Gelderen DV, Lawlor M, Wada M, Joon ML, Quong G, Khoo V. Towards individualised radiotherapy for Stage I seminoma. Radiother Oncol 2005, 76(3):251-6. 10.1016/j.radonc.2005.08.005, 16169622.
56. Zouhair A, Ozsahin M, Schaffer M, Albrecht S, Camus F, Jichlinski P, Mirimanoff RO, Bischof Delaloye A, Meuwly JY, Prior JO. Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers. Curr Med Chem 2010, 17(23):2492-502. 10.2174/092986710791556014, 20491646.
57. Oliver RT, Edmonds PM, Ong JY, Ostrowski MJ, Jackson AW, Baille-Johnson H, Williams MV, Wiltshire CR, Mott T, Pratt WR. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?. Int J Radiat Oncol Biol Phys 1994, 29(1):3-8. 10.1016/0360-3016(94)90219-4, 8175442.
58. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP, . MRC TE19 collaborators and the EORTC 30982 collaborators Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005, 366(9482):293-300. 10.1016/S0140-6736(05)66984-X, 16039331, MRC TE19 collaborators and the EORTC 30982 collaborators.
59. Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer 2002, 38(1):11-6. 10.1016/S0959-8049(01)00340-9, 11750834.
60. Mead GM, Fossa SD, Oliver RT, Fogarty PJ, Pollock P, Stenning SP. Relapse patterns in 2,466 stage 1 seminoma patients (pts) entered into Medical Research Council randomised trials. J Clin Oncol (Meeting Abstracts) 2008, 26:5020.
61. AJCC Cancer Staging Manual. Ann Oncol 2010, 21(5):140-6. Springer Verlag New York, 6, 10.1093/annonc/mdq176, 19887468, AJCC.
62. Schmidberger H, Bamberg M, Meisner C, Classen J, Winkler C, Hartmann M, Templin R, Wiegel T, Dornoff W, Ross D, Thiel HJ, Martini C, Haase W. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys 1997, 39(2):321-6.
63. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Köhrmann KU, Bamberg M. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003, 21(6):1101-6. 10.1200/JCO.2003.06.065, 12637477.
64. Patterson H, Norman AR, Mitra SS, Nicholls J, Fisher C, Dearnaley DP, Horwich A, Mason MD, Huddart RA. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol 2001, 59(1):5-11. 10.1016/S0167-8140(00)00240-1, 11295200.
65. Arranz Arija JA, García del Muro X, Gumà J, Aparicio J, Salazar R, Saenz A, Carles J, Sánchez M, Germà-Lluch JR. E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience. Ann Oncol 2001, 12(4):487-91. 10.1023/A:1011127715764, 11398880.
66. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G, Greco FA. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989, 7(3):387-91.
67. Domont J, Laplanche A, de Crevoisier R, Theodore C, Wibault P, Fizazi K. A risk-adapted strategy of radiotherapy and cisplatin-based chemotherapy in stage II seminoma: results of a 20-year experience (abstract). J Clin Oncol 2005, 23(16):4571.
68. Chung PW, Warde PR, Panzarella T, Bayley AJ, Catton CN, Milosevic MF, Jewett MA, Sturgeon JF, Moore M, Gospodarowicz MK. Appropriate radiation volume for stage IIA/B testicular seminoma. Int J Radiat Oncol Biol Phys 2003, 56(3):746-8. 10.1016/S0360-3016(03)00011-7, 12788180.
69. Lederman GS, Sheldon TA, Chaffey JT, Herman TS, Gelman RS, Coleman CN. Cardiac disease after mediastinal irradiation for seminoma. Cancer 1987, 60(4):772-6. 10.1002/1097-0142(19870815)60:4<772::AID-CNCR2820600411>3.0.CO;2-A, 3594400.
70. von der Maase H. Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB?. Radiother Oncol 2001, 59(1):1-3. 10.1016/S0167-8140(01)00344-9, 11295199.
71. Krege S, Boergermann C, Baschek R, Hinke A, Pottek T, Kliesch S, Dieckmann KP, Albers P, Knutzen B, Weinknecht S, Schmoll HJ, Beyer J, Ruebben H, . German Testicular Cancer Study Group (GTCSG) German Testicular Cancer Study Group (GTCSG). Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 2006, 17(2):276-80. German Testicular Cancer Study Group (GTCSG).
72. Gilbert DC, Pudney D, Van As N, Dearnaley D, Horwich A, Huddart R. Early outcomes of treating stage IIA/B seminoma with a single cycle of carboplatin and radiotherapy (abstract). J Clin Oncol 2009, 27(12):2101-2. 10.1200/JCO.2008.21.5269, 19289608.
73. Jacobsen GK, Mellemgaard A, Engelholm SA, Moller H. Increased incidence of sarcoma in patients treated for testicular seminoma. Eur J Cancer 1993, 29A:664-8.
74. Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M, Jewett M. Management of stage II seminoma. J Clin Oncol 1998, 16(1):290-4.
75. Fosså SD, Oliver RT, Stenning SP, Horwich A, Wilkinson P, Read G, Mead GM, Roberts JT, Rustin G, Cullen MH, Kaye SB, Harland SJ, Cook P. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 1997, 33(9):1380-7. 10.1016/S0959-8049(96)00425-X, 9337678.
76. Duchesne GM, Stenning SP, Aass N, Mead GM, Fosså SD, Oliver RT, Horwich A, Read G, Roberts IT, Rustin G, Cullen MH, Kaye SB, Harland SJ, Cook PA. Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997, 33(6):829-35. 10.1016/S0959-8049(97)00033-6, 9291801.
77. Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann JT, Horwich A, Clemm C, Gerl A, Meisner C, Rückerl CP, Schmoll HJ, Kanz L, Oliver T. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer 2004, 91(4):683-7. 2364800, 15266338.
78. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998, 16(4):1287-93.
79. Gholam D, Fizazi K, Terrier-Lacombe MJ, Jan P, Culine S, Theodore C. Advanced seminoma-treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. Cancer 2003, 98(4):745-52. 10.1002/cncr.11574, 12910518.
80. Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994, 12(1):120-6.
81. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007, 25(28):4370-8. 10.1200/JCO.2006.10.5296, 17906202.
82. Giannis M, Aristotelis B, Vassiliki K, Ioannis A, Konstantinos S, Nikolaos A, Georgios P, Georgios P, Pantelis P, Meletios-Athanasios D. Cisplatin-based chemotherapy for advanced seminoma: report of 52 cases treated in two institutions. J Cancer Res Clin Oncol 2009, 135(11):1495-500. 10.1007/s00432-009-0596-2, 19437039.
83. Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002, 168(5):1975-9. 10.1016/S0022-5347(05)64275-9, 12394688.
84. Miller KD, Loehrer PJ, Gonin R, Einhorn LH. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 1997, 15(4):1427-31.
85. Culine S, Abs L, Terrier-Lacombe MJ, Théodore C, Wibault P, Droz JP. Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience. Eur J Cancer 1998, 34(3):353-8.
86. Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V, Bajorin DF, Bosl GJ, Motzer RJ. Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 2002, 20(1):297-301. 10.1200/JCO.20.1.297, 11773182.
87. Puc HS, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V, Bajorin DF, Bosl GJ, Mencel P, Motzer RJ. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996, 14(2):454-60.
88. Motzer RJ, Bosl GJ, Geller NL, Penenberg D, Yagoda A, Golbey R, Whitmore WF, Fair WR, Sogani P, Herr H. Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann Intern Med 1988, 108(4):513-8.
89. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993, 11(2):324-9.
90. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004, 22(6):1034-9. 10.1200/JCO.2004.07.188, 15020605.
91. George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC, Jung SH, Shen J, Finch DE, Kelley MR, Einhorn LH. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 2003, 21(1):113-22. 10.1200/JCO.2003.03.019, 12506179.
92. Djeffal C, Demailly M, Tillou X, Saint F, Petit J. Place of serum HCG assay in the follow-up of non-HCG-secreting testicular seminomas. Prog Urol 2008, 18(10):654-6. 10.1016/j.purol.2008.04.024, 18971108.
93. Hori K, Uematsu K, Yasoshima H, Yamada A, Sakurai K, Ohya M. Testicular seminoma with human chorionic gonadotropin production. Pathol Int 1997, 47(9):592-9. 10.1111/j.1440-1827.1997.tb04547.x, 9311009.
94. Mirimanoff RO, Sinzig M, Krüger M, Miralbell R, Thöni A, Ries G, Bosset JF, Bernier J, Bolla M, Nguyen TD. Prognosis of human chorionic gonadotropin-producing seminoma treated by postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1993, 27(1):17-23. 10.1016/0360-3016(93)90416-S, 8365938.
95. Rüther U, Rothe B, Grunert K, Bader H, Sessler R, Nunnensiek C, Rassweiler J, Lüthgens M, Eisenberger F, Jipp P. Role of human chorionic gonadotropin in patients with pure seminoma. Eur Urol 1994, 26(2):129-33.
96. Neill M, Warde P, Fleshner N. Management of low-stage testicular seminoma. Urol Clin North Am 2007, 34(2):127-36. 10.1016/j.ucl.2007.02.009, 17484918.
97. Bruns F, Raub M, Schaefer U, Micke O. No predictive value of beta-hCG in patients with stage I seminoma-results of a long-term follow-up study after adjuvant radiotherapy. Anticancer Res 2005, 25(3A):1543-6.
98. Weissbach L, Bussar-Maatz R, Löhrs U, Schubert GE, Mann K, Hartmann M, Dieckmann KP, Fassbinder J. Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study.Seminoma Study Group. Eur Urol 1999, 36(6):601-8. 10.1159/000020055, 10559615.
99. Belkacémi Y, Zouhair A, Ozsahin M, Azria D, Mirimanoff RO, . Réseau des Cancers Rares (Rare Cancer Network) Prognostic factors and management of rare cancers. Cancer Radiother 2006, 10:317-322. Réseau des Cancers Rares (Rare Cancer Network).